- Home
- JL vs NXL Comparison
JL vs NXL Comparison
Compare JL & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JL
- NXL
- Stock Information
- Founded
- JL 1985
- NXL 2010
- Country
- JL Hong Kong
- NXL United States
- Employees
- JL N/A
- NXL N/A
- Industry
- JL
- NXL Medical Specialities
- Sector
- JL
- NXL Health Care
- Exchange
- JL NYSE
- NXL Nasdaq
- Market Cap
- JL 10.1M
- NXL 10.0M
- IPO Year
- JL 2024
- NXL 2022
- Fundamental
- Price
- JL $5.31
- NXL $3.16
- Analyst Decision
- JL
- NXL Hold
- Analyst Count
- JL 0
- NXL 1
- Target Price
- JL N/A
- NXL N/A
- AVG Volume (30 Days)
- JL 65.3K
- NXL 445.0K
- Earning Date
- JL 07-31-2024
- NXL 11-08-2024
- Dividend Yield
- JL N/A
- NXL N/A
- EPS Growth
- JL N/A
- NXL N/A
- EPS
- JL 0.26
- NXL N/A
- Revenue
- JL $28,378,669.00
- NXL $162,078.00
- Revenue This Year
- JL N/A
- NXL $56.86
- Revenue Next Year
- JL N/A
- NXL $167.44
- P/E Ratio
- JL $20.50
- NXL N/A
- Revenue Growth
- JL N/A
- NXL 26.00
- 52 Week Low
- JL $0.23
- NXL $0.25
- 52 Week High
- JL $29.95
- NXL $4.49
- Technical
- Relative Strength Index (RSI)
- JL 71.16
- NXL 51.05
- Support Level
- JL $4.53
- NXL $2.55
- Resistance Level
- JL $6.25
- NXL $3.11
- Average True Range (ATR)
- JL 0.59
- NXL 0.32
- MACD
- JL 0.04
- NXL 0.03
- Stochastic Oscillator
- JL 66.78
- NXL 70.71
About JL J-LONG GROUP LIMITED
J-Long Group Ltd is an established distributor in Hong Kong of reflective and non-reflective garment trims including, among others, heat transfers, fabrics, woven labels and tapes, sewing badges, piping, zipper pullers and drawcords. It also offers a wide range of apparel solution services to cater to its customers' needs for reflective and non-reflective garment trims, ranging from market trend analysis, product design and development and production to quality control.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.